JP6001560B2 - Ｈｉｖ成熟阻害活性を有するｃ−１７およびｃ−３修飾トリテルペノイド - Google Patents
Ｈｉｖ成熟阻害活性を有するｃ−１７およびｃ−３修飾トリテルペノイド Download PDFInfo
- Publication number
- JP6001560B2 JP6001560B2 JP2013551362A JP2013551362A JP6001560B2 JP 6001560 B2 JP6001560 B2 JP 6001560B2 JP 2013551362 A JP2013551362 A JP 2013551362A JP 2013551362 A JP2013551362 A JP 2013551362A JP 6001560 B2 JP6001560 B2 JP 6001560B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- substituted
- cyclopenta
- pentamethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C[C@](C1)([C@@]1C1)C(C)(C)[C@](C)(*)C1C1CC1 Chemical compound C[C@](C1)([C@@]1C1)C(C)(C)[C@](C)(*)C1C1CC1 0.000 description 17
- BYGNXQVPFCTQRQ-UHFFFAOYSA-N CNCCS(=O)=O Chemical compound CNCCS(=O)=O BYGNXQVPFCTQRQ-UHFFFAOYSA-N 0.000 description 2
- QWVLBBPXSQJARZ-RTLCBTMGSA-N CC(C)(C)OC(N1CCN(CCN[C@@](CC[C@H]2C(C)=C)(CC3)C2[C@@H](CC2)[C@]3(C)[C@](C)(CC3)C2[C@]2(C)C3C(C)(C)C(c(cc3)ccc3C(O)=O)=CC2)CC1)=O Chemical compound CC(C)(C)OC(N1CCN(CCN[C@@](CC[C@H]2C(C)=C)(CC3)C2[C@@H](CC2)[C@]3(C)[C@](C)(CC3)C2[C@]2(C)C3C(C)(C)C(c(cc3)ccc3C(O)=O)=CC2)CC1)=O QWVLBBPXSQJARZ-RTLCBTMGSA-N 0.000 description 1
- YGIMWQYOELXDTN-XPGNLXOLSA-N CC(C)(C)OC(N1CCN(CCN[C@@](CC[C@H]2C(C)=C)(CC3)C2[C@@H](CC2)[C@]3(C)[C@](C)(CC3)C2[C@]2(C)C3C(C)(C)C(c(cc3)ccc3C(OC)=O)=CC2)CC1)=O Chemical compound CC(C)(C)OC(N1CCN(CCN[C@@](CC[C@H]2C(C)=C)(CC3)C2[C@@H](CC2)[C@]3(C)[C@](C)(CC3)C2[C@]2(C)C3C(C)(C)C(c(cc3)ccc3C(OC)=O)=CC2)CC1)=O YGIMWQYOELXDTN-XPGNLXOLSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N CC(C)(C)OC(N1CCNCC1)=O Chemical compound CC(C)(C)OC(N1CCNCC1)=O CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- FQBSNYKEVQRTGJ-CJBPRDETSA-N CC(C)(C1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)C1C([C@@H](CC1)C(C)=C)[C@@]21NC(OCCCN(CC1)CCS1(=O)=O)=O Chemical compound CC(C)(C1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)C1C([C@@H](CC1)C(C)=C)[C@@]21NC(OCCCN(CC1)CCS1(=O)=O)=O FQBSNYKEVQRTGJ-CJBPRDETSA-N 0.000 description 1
- JJBDPUIADXRHAM-SJWZJFCOSA-N CC(C)(C1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C(C(CC1)C(C)=C)[C@@]21NC(CN(C1)CC1(F)F)=O Chemical compound CC(C)(C1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C(C(CC1)C(C)=C)[C@@]21NC(CN(C1)CC1(F)F)=O JJBDPUIADXRHAM-SJWZJFCOSA-N 0.000 description 1
- XDMUFNNPLXHNKA-UOBQYIRLSA-N CC(C)(C1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21NCCN(CC1)CCS1(=O)=O Chemical compound CC(C)(C1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21NCCN(CC1)CCS1(=O)=O XDMUFNNPLXHNKA-UOBQYIRLSA-N 0.000 description 1
- IHYUWIZUYGJJIZ-IWGVNVMRSA-N CC(C)(C1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21NCCN(CCC1)C1=O Chemical compound CC(C)(C1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21NCCN(CCC1)C1=O IHYUWIZUYGJJIZ-IWGVNVMRSA-N 0.000 description 1
- YWAOPMYURACBJP-OOCSKDHWSA-N CC(C)(C1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21N Chemical compound CC(C)(C1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21N YWAOPMYURACBJP-OOCSKDHWSA-N 0.000 description 1
- AISLWPVTCPKMJI-MMSIMHLJSA-N CC(C)(C1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21NC(CBr)=O Chemical compound CC(C)(C1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21NC(CBr)=O AISLWPVTCPKMJI-MMSIMHLJSA-N 0.000 description 1
- ZHNKUNSJZUCWBD-FKDSFBNWSA-N CC(C)(C1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21NC(CN(C1)CC1(F)F)=O Chemical compound CC(C)(C1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21NC(CN(C1)CC1(F)F)=O ZHNKUNSJZUCWBD-FKDSFBNWSA-N 0.000 description 1
- JFNBJKABAZREHW-VYVBUBKVSA-N CC(C)(C1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21NCCN(CC1)CCS1(=O)=O Chemical compound CC(C)(C1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)[C@H]1C([C@@H](CC1)C(C)=C)[C@@]21NCCN(CC1)CCS1(=O)=O JFNBJKABAZREHW-VYVBUBKVSA-N 0.000 description 1
- JHXCYXAOEJTMFI-NNWDMIHZSA-N CC(C)(C1CC2)C(c3ccc(C(O)=O)c(F)c3)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)C1C(CCC1)C21NCCN(CCC1)C1=O Chemical compound CC(C)(C1CC2)C(c3ccc(C(O)=O)c(F)c3)=CC[C@]1(C)C(CC1)[C@]2(C)[C@](C)(CC2)C1C(CCC1)C21NCCN(CCC1)C1=O JHXCYXAOEJTMFI-NNWDMIHZSA-N 0.000 description 1
- GUGJFDYYKQWAFY-RLSSSYFUSA-N CC(C)([C@@H]1CC2)C(c(cc3)cc(F)c3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCN(CC1)CCS1(=O)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)cc(F)c3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCN(CC1)CCS1(=O)=O GUGJFDYYKQWAFY-RLSSSYFUSA-N 0.000 description 1
- OYAHCYCTSFKNPU-FSVNXHQXSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H](C(CC1)C(C)=C)[C@@]21NC(CN(C)C(CC1)CS1(=O)=O)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H](C(CC1)C(C)=C)[C@@]21NC(CN(C)C(CC1)CS1(=O)=O)=O OYAHCYCTSFKNPU-FSVNXHQXSA-N 0.000 description 1
- OASIVQNLIIJMLP-QSIOBENTSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(CCCN(C)C)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(CCCN(C)C)=O OASIVQNLIIJMLP-QSIOBENTSA-N 0.000 description 1
- UQQINAJJQRKTJI-ZVJJJHPOSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(CN(c1cc(Cl)ccc1CO1)C1=O)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(CN(c1cc(Cl)ccc1CO1)C1=O)=O UQQINAJJQRKTJI-ZVJJJHPOSA-N 0.000 description 1
- GLZZVNCQMVOTRR-QSIOBENTSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(CN1CCOCC1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(CN1CCOCC1)=O GLZZVNCQMVOTRR-QSIOBENTSA-N 0.000 description 1
- ABHNQIOWBISBEJ-DJZGOYIYSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(C[n]1c2ccccc2cc1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(C[n]1c2ccccc2cc1)=O ABHNQIOWBISBEJ-DJZGOYIYSA-N 0.000 description 1
- ZPRJWSXBZDMOHA-PQBBHEMQSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(N(CCN(C)C)CCO)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(N(CCN(C)C)CCO)=O ZPRJWSXBZDMOHA-PQBBHEMQSA-N 0.000 description 1
- XXYDPDHEVQQOOZ-NFEAHYNFSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(N(CCN1)CC1=O)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(N(CCN1)CC1=O)=O XXYDPDHEVQQOOZ-NFEAHYNFSA-N 0.000 description 1
- RQRKMYCFISPBBY-WECSNRJHSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(N1CCN(C)CC1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(N1CCN(C)CC1)=O RQRKMYCFISPBBY-WECSNRJHSA-N 0.000 description 1
- ZHZLXPYNSCWUGX-WECSNRJHSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(N1CCNCCC1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(N1CCNCCC1)=O ZHZLXPYNSCWUGX-WECSNRJHSA-N 0.000 description 1
- AQCBMRIJWMNIGN-WYJOASSBSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(NC1(CN2CCCCC2)CC1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(NC1(CN2CCCCC2)CC1)=O AQCBMRIJWMNIGN-WYJOASSBSA-N 0.000 description 1
- VGKROGOCYRVUEN-PQBBHEMQSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(NCCC[n]1cncc1)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(NCCC[n]1cncc1)=O VGKROGOCYRVUEN-PQBBHEMQSA-N 0.000 description 1
- QASSSLZQIDWHOB-LYJCWSOSSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(NCCN(C)C)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(NCCN(C)C)=O QASSSLZQIDWHOB-LYJCWSOSSA-N 0.000 description 1
- VJCOSSYTGQQZIU-LTJMNYHZSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(OCCCCN(CC1)CCS1(=O)=O)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(OCCCCN(CC1)CCS1(=O)=O)=O VJCOSSYTGQQZIU-LTJMNYHZSA-N 0.000 description 1
- NHIGHKDCJXTDSV-NNOKGMCDSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCN(CC1)CCN1C(C)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCN(CC1)CCN1C(C)=O NHIGHKDCJXTDSV-NNOKGMCDSA-N 0.000 description 1
- FFSBSDYATDEFDZ-FJMUSEAASA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCN1CCN(C)CC1 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCN1CCN(C)CC1 FFSBSDYATDEFDZ-FJMUSEAASA-N 0.000 description 1
- KGCBDIJYPDRXJJ-NNOKGMCDSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCNc1ccccc1 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCNc1ccccc1 KGCBDIJYPDRXJJ-NNOKGMCDSA-N 0.000 description 1
- AWRIISJQIWZBKG-RPSIQIFRSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCNc1nc(SC)ccn1 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCNc1nc(SC)ccn1 AWRIISJQIWZBKG-RPSIQIFRSA-N 0.000 description 1
- LLMRAPIERIHZOY-WECSNRJHSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCNc1ncc[n]1C Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCNc1ncc[n]1C LLMRAPIERIHZOY-WECSNRJHSA-N 0.000 description 1
- CQICLCMCGHJSQL-LYJCWSOSSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCNc1ncc[s]1 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(O)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCCNc1ncc[s]1 CQICLCMCGHJSQL-LYJCWSOSSA-N 0.000 description 1
- CWKKIZCMKSXJOQ-LCYMYPGXSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21N=C=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21N=C=O CWKKIZCMKSXJOQ-LCYMYPGXSA-N 0.000 description 1
- UWERXWZDTULCPU-NFKLAVEJSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(CN(CC1)CCC1(F)F)=O Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NC(CN(CC1)CCC1(F)F)=O UWERXWZDTULCPU-NFKLAVEJSA-N 0.000 description 1
- LBTVWJCPUQFTDU-NFKLAVEJSA-N CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCc1ccnc(F)c1 Chemical compound CC(C)([C@@H]1CC2)C(c(cc3)ccc3C(OC)=O)=CC[C@]1(C)[C@@H](CC1)[C@]2(C)[C@](C)(CC2)[C@H]1[C@@H]([C@@H](CC1)C(C)=C)[C@@]21NCc1ccnc(F)c1 LBTVWJCPUQFTDU-NFKLAVEJSA-N 0.000 description 1
- UMOIFYOLNHAAML-HVLWHFFDSA-N CC(C)CN[C@@](CCC1)(CC2)[C@H]1[C@@H](CC1)[C@]2(C)[C@](C)(CC2)C1[C@]1(C)C2C(C)(C)C(c(cc2)ccc2C(O)=O)=CC1 Chemical compound CC(C)CN[C@@](CCC1)(CC2)[C@H]1[C@@H](CC1)[C@]2(C)[C@](C)(CC2)C1[C@]1(C)C2C(C)(C)C(c(cc2)ccc2C(O)=O)=CC1 UMOIFYOLNHAAML-HVLWHFFDSA-N 0.000 description 1
- AMHSNZCPOYHRAQ-HOEBOJOYSA-N CC(C)[C@H](CC1)C([C@@H](CC2)[C@@](C)(CC3)[C@](C)(CC4)C2[C@]2(C)C4C(C)(C)C(c(cc4)ccc4C(OC)=O)=CC2)[C@]13N=C=O Chemical compound CC(C)[C@H](CC1)C([C@@H](CC2)[C@@](C)(CC3)[C@](C)(CC4)C2[C@]2(C)C4C(C)(C)C(c(cc4)ccc4C(OC)=O)=CC2)[C@]13N=C=O AMHSNZCPOYHRAQ-HOEBOJOYSA-N 0.000 description 1
- OKFBTZKRAUFMNK-VOTSOKGWSA-N CC/C(/F)=C\C(C)(C)OC Chemical compound CC/C(/F)=C\C(C)(C)OC OKFBTZKRAUFMNK-VOTSOKGWSA-N 0.000 description 1
- KUTPRXZITXHULJ-BAMHPCRESA-N CCC(C)(C)C(CC1)CC(CC2)[C@]1(C)[C@](C)(CC1)[C@H]2C(CCC2)[C@@]12N Chemical compound CCC(C)(C)C(CC1)CC(CC2)[C@]1(C)[C@](C)(CC1)[C@H]2C(CCC2)[C@@]12N KUTPRXZITXHULJ-BAMHPCRESA-N 0.000 description 1
- QZKZCEBFLZYBGQ-DOGNIXTISA-N CC[C@@H]1C(C)[C@@]2(C)[C@@H](C)[C@H](C)[C@@H](C)[C@H](C(C=C)C(OC)=O)C(C)(C)C2CC1 Chemical compound CC[C@@H]1C(C)[C@@]2(C)[C@@H](C)[C@H](C)[C@@H](C)[C@H](C(C=C)C(OC)=O)C(C)(C)C2CC1 QZKZCEBFLZYBGQ-DOGNIXTISA-N 0.000 description 1
- BIKULLBDZQBSQL-UHFFFAOYSA-N CN(c1c(CO2)ccc(Cl)c1)C2=O Chemical compound CN(c1c(CO2)ccc(Cl)c1)C2=O BIKULLBDZQBSQL-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- VIRSIQNRLMQTIL-JBOOICDFSA-N C[C@@H](CC(C(C)(C)C(c(cc1)ccc1C(OC)=O)=CC1)[C@@]1(C)C1CC2)C1[C@](C)(CC1)[C@H]2C(C(CC2)C(C)=C)[C@@]12NCCCl Chemical compound C[C@@H](CC(C(C)(C)C(c(cc1)ccc1C(OC)=O)=CC1)[C@@]1(C)C1CC2)C1[C@](C)(CC1)[C@H]2C(C(CC2)C(C)=C)[C@@]12NCCCl VIRSIQNRLMQTIL-JBOOICDFSA-N 0.000 description 1
- QUHVRXKSQHIZNV-UHFFFAOYSA-N FC1(CNC1)F Chemical compound FC1(CNC1)F QUHVRXKSQHIZNV-UHFFFAOYSA-N 0.000 description 1
- HHEKNWQXFVOUNJ-UHFFFAOYSA-N NCCN(CCC1)C1=O Chemical compound NCCN(CCC1)C1=O HHEKNWQXFVOUNJ-UHFFFAOYSA-N 0.000 description 1
- KWGFISNERABFPJ-UHFFFAOYSA-N O=S1(CCN(CCCl)CC1)=O Chemical compound O=S1(CCN(CCCl)CC1)=O KWGFISNERABFPJ-UHFFFAOYSA-N 0.000 description 1
- VAJSFWFPXNWBLF-UHFFFAOYSA-N OCCCN(CC1)CCS1(=O)=O Chemical compound OCCCN(CC1)CCS1(=O)=O VAJSFWFPXNWBLF-UHFFFAOYSA-N 0.000 description 1
- MPACUVIDHVFZBK-UHFFFAOYSA-N OCCNC(CC1)CS1(=O)=O Chemical compound OCCNC(CC1)CS1(=O)=O MPACUVIDHVFZBK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161437893P | 2011-01-31 | 2011-01-31 | |
| US61/437,893 | 2011-01-31 | ||
| PCT/US2012/022852 WO2012106190A1 (en) | 2011-01-31 | 2012-01-27 | C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014503595A JP2014503595A (ja) | 2014-02-13 |
| JP2014503595A5 JP2014503595A5 (enExample) | 2015-02-26 |
| JP6001560B2 true JP6001560B2 (ja) | 2016-10-05 |
Family
ID=45567147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013551362A Expired - Fee Related JP6001560B2 (ja) | 2011-01-31 | 2012-01-27 | Ｈｉｖ成熟阻害活性を有するｃ−１７およびｃ−３修飾トリテルペノイド |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US8846647B2 (enExample) |
| EP (1) | EP2670765B1 (enExample) |
| JP (1) | JP6001560B2 (enExample) |
| KR (1) | KR101886467B1 (enExample) |
| CN (1) | CN103429607B (enExample) |
| AR (1) | AR085053A1 (enExample) |
| AU (1) | AU2012212509B2 (enExample) |
| BR (1) | BR112013019419A2 (enExample) |
| CA (1) | CA2826113C (enExample) |
| CL (1) | CL2013002185A1 (enExample) |
| CO (1) | CO6751275A2 (enExample) |
| EA (1) | EA022470B1 (enExample) |
| ES (1) | ES2653847T3 (enExample) |
| IL (1) | IL227678B (enExample) |
| MA (1) | MA34909B1 (enExample) |
| MY (1) | MY162186A (enExample) |
| PE (1) | PE20141152A1 (enExample) |
| PH (1) | PH12013501528A1 (enExample) |
| PT (1) | PT2670765T (enExample) |
| SG (1) | SG192144A1 (enExample) |
| TN (1) | TN2013000321A1 (enExample) |
| TW (1) | TWI628188B (enExample) |
| UY (1) | UY33886A (enExample) |
| WO (1) | WO2012106190A1 (enExample) |
| ZA (1) | ZA201306546B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015510515A (ja) * | 2012-02-15 | 2015-04-09 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｉｖ成熟阻害活性のあるｃ−３シクロアルケニルトリテルペノイド |
| JP2015516422A (ja) * | 2012-05-07 | 2015-06-11 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｉｖ成熟阻害活性を有するｃ−１７二環式アミンのトリテルペノイド |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201006474A (en) | 2008-04-18 | 2010-02-16 | Reata Pharmaceuticals Inc | Natural products including an anti-flammatory pharmacore and methods of use |
| EP2279197B1 (en) | 2008-04-18 | 2014-11-05 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring |
| RS58392B1 (sr) | 2008-04-18 | 2019-04-30 | Reata Pharmaceuticals Inc | Antioksidantni modulatori inflamacije: derivati oleanoličke kiseline sa amino i drugim modifikacijama na c-17 |
| HUE033288T2 (en) | 2008-04-18 | 2017-11-28 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: C-17 homologated oleic acid derivatives |
| ES2653717T3 (es) | 2010-12-17 | 2018-02-08 | Reata Pharmaceuticals, Inc. | Pirazolil- y pirimidinil-enonas tricíclicas como moduladores antioxidantes de la inflamación |
| HRP20151212T1 (hr) * | 2011-01-31 | 2015-12-04 | Bristol-Myers Squibb Company | C-28 AMINI C-3 MODIFICIRANIH DERIVATA BETULINSKE KISELINE KAO INHIBITORI SAZRIJEVANJA HIV-a P |
| EA026847B1 (ru) | 2011-03-11 | 2017-05-31 | Рита Фармасьютикалз, Инк. | C4-монометилтритерпеноидные производные и способы их применения |
| EP2758419B8 (en) | 2011-09-21 | 2017-04-19 | VIIV Healthcare UK (No.5) Limited | Novel betulinic acid derivatives with antiviral activity |
| EP2841445B1 (en) | 2012-04-27 | 2017-06-14 | Reata Pharmaceuticals, Inc. | 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
| US9556222B2 (en) | 2012-06-15 | 2017-01-31 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| JP6389174B2 (ja) * | 2012-08-15 | 2018-09-12 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | 化学的方法 |
| TWI630212B (zh) | 2012-09-10 | 2018-07-21 | 瑞塔醫藥有限責任公司 | 丁香油素（ｏｌｅａｎｏｌｉｃ ａｃｉｄ）之ｃ１７－烷二基與烯二基衍生物及其使用方法 |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| EA027371B1 (ru) * | 2013-02-06 | 2017-07-31 | Бристол-Майерс Сквибб Компани | C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич |
| BR112015019590A2 (pt) * | 2013-02-25 | 2017-07-18 | Bristol Myers Squibb Co | derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv |
| MX374543B (es) | 2014-04-11 | 2025-03-06 | Viiv Healthcare Uk No 4 Ltd | Triterpenoides con actividad inhibidora de la maduración del virus de inmunodeficiencia humana, sustituidos en la posición 3 con un anillo no aromático que lleva un sustituyente haloalquilo. |
| US9920090B2 (en) | 2014-06-19 | 2018-03-20 | VIIV Healthcare UK (No.5) Limited | Betulinic acid derivatives with HIV maturation inhibitory activity |
| RU2017118576A (ru) * | 2014-11-14 | 2018-12-14 | ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД | C-17-арил-замещённые аналоги бетулиновой кислоты |
| AU2015346303B2 (en) | 2014-11-14 | 2018-03-15 | VIIV Healthcare UK (No.5) Limited | Oxolupene derivatives |
| JP2018512433A (ja) * | 2015-04-14 | 2018-05-17 | ヴィーブ ヘルスケア ユーケー（ナンバー４）リミテッド | Ｈｉｖ成熟阻害剤の製造方法 |
| RU2018105352A (ru) | 2015-07-28 | 2019-08-29 | ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед | Производные бетулина для предупреждения или лечения ВИЧ-инфекций |
| KR20180028534A (ko) | 2015-07-28 | 2018-03-16 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체 |
| WO2017025901A1 (en) * | 2015-08-11 | 2017-02-16 | Hetero Research Foundation | Novel c28-analogues with c3-modifications of triterpene derivatives as hiv inhibitors |
| BR112018005861B1 (pt) | 2015-09-23 | 2022-11-22 | Reata Pharmaceuticals, Inc | Compostos derivados de ácido oleanólico modificado com c4 para a inibição de il-17, composição farmacêutica e usos terapêuticos dos ditos compostos |
| RU2018112958A (ru) | 2015-09-24 | 2019-10-28 | ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед | Соединения с ингибирующей созревание ВИЧ активностью |
| RU2018116772A (ru) | 2015-11-20 | 2019-12-20 | ВАЙВ ХЕЛТКЕР ЮКей (N4) ЛИМИТЕД | Композиции ингибитора созревания ВИЧ |
| CN108699103A (zh) * | 2016-01-20 | 2018-10-23 | 葛兰素史克知识产权第二有限公司 | 具有hiv成熟抑制活性的羽扇烷类的胺衍生物 |
| AR107512A1 (es) * | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
| EP3478703A1 (en) * | 2016-06-30 | 2019-05-08 | ViiV Healthcare UK (No.5) Limited | Triterpenoid inhibitors of human immunodeficiency virus replication |
| WO2018044822A1 (en) * | 2016-08-31 | 2018-03-08 | Viiv Healthcare Company | Combinations and uses and treatments thereof |
| CN111386279A (zh) | 2017-08-04 | 2020-07-07 | 阿德利克斯股份有限公司 | 用于治疗高钾血症的甘草次酸衍生物 |
| JP6977474B2 (ja) * | 2017-10-23 | 2021-12-08 | 東京エレクトロン株式会社 | 半導体装置の製造方法 |
| JP6926939B2 (ja) * | 2017-10-23 | 2021-08-25 | 東京エレクトロン株式会社 | 半導体装置の製造方法 |
| JP7436385B2 (ja) | 2018-04-24 | 2024-02-21 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | Ｈｉｖ成熟阻害活性を有する化合物 |
| PL237998B1 (pl) | 2018-05-28 | 2021-06-28 | Narodowy Inst Lekow | Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie |
| US12060340B2 (en) | 2018-06-20 | 2024-08-13 | Reata Pharmaceuticals, Inc | Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith |
| JP7735185B2 (ja) | 2019-02-07 | 2025-09-08 | アルデリックス， インコーポレイテッド | 高カリウム血症の治療で使用するためのグリチルレチン酸誘導体 |
| JP7648531B2 (ja) | 2019-02-11 | 2025-03-18 | ヘテロ ラボズ リミテッド | Ｈｉｖ阻害剤としての新規トリテルペン誘導体 |
| CN120248001A (zh) | 2019-07-19 | 2025-07-04 | 里亚塔医药公司 | C17极性的-取代的杂芳族合成三萜类化合物及其使用方法 |
| GB2598300A (en) * | 2020-08-21 | 2022-03-02 | Univ Durham | Cross-linking method and applications in bioconjugation |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5962527A (en) | 1995-03-21 | 1999-10-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for treating cancers |
| US5869535A (en) | 1995-03-21 | 1999-02-09 | The Board Of Trustees Of The University Of Illinois | Method and composition for selectively inhibiting melanoma |
| US5679828A (en) | 1995-06-05 | 1997-10-21 | Biotech Research Labs, Inc. | Betulinic acid and dihydrobetulinic acid derivatives and uses therefor |
| US20020137755A1 (en) | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US7365221B2 (en) | 2002-09-26 | 2008-04-29 | Panacos Pharmaceuticals, Inc. | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| US20050014730A1 (en) | 2003-04-02 | 2005-01-20 | Carlson Robert M. | Anti-fungal formulation of triterpene and essential oil |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| EP1730163A4 (en) | 2004-03-17 | 2009-12-30 | Panacos Pharmaceuticals Inc | Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid |
| TW200628161A (en) | 2004-11-12 | 2006-08-16 | Panacos Pharmaceuticals Inc | Novel betulin derivatives, preparation thereof and use thereof |
| US8067620B2 (en) | 2005-05-04 | 2011-11-29 | Medicines For Malaria Venture Mmv | Dispiro 1,2,4-trioxolane antimalarials |
| WO2008127364A2 (en) | 2006-10-13 | 2008-10-23 | Myriad Genetics, Inc. | Antiviral compounds and use thereof |
| WO2008115281A2 (en) | 2006-10-16 | 2008-09-25 | Myriad Genetics, Inc. | Compounds for treating viral infections |
| JP2011511812A (ja) * | 2008-02-14 | 2011-04-14 | バイロケム ファーマ インコーポレイテッド | 新規１７βルパン誘導体 |
| US9067966B2 (en) | 2009-07-14 | 2015-06-30 | Hetero Research Foundation, Hetero Drugs Ltd. | Lupeol-type triterpene derivatives as antivirals |
| BR112012030810A2 (pt) * | 2010-06-04 | 2019-09-24 | Bristol-Myers Squibb Company | "c-28 amidas de derivados de ácido c-3 betulínico modificados como inibidores de maturação de hiv" |
| CA2801487C (en) * | 2010-06-04 | 2017-12-05 | Bristol-Myers Squibb Company | Modified c-3 betulinic acid derivatives as hiv maturation inhibitors |
-
2012
- 2012-01-27 WO PCT/US2012/022852 patent/WO2012106190A1/en not_active Ceased
- 2012-01-27 MA MA36183A patent/MA34909B1/fr unknown
- 2012-01-27 ES ES12702947.8T patent/ES2653847T3/es active Active
- 2012-01-27 US US13/359,727 patent/US8846647B2/en active Active
- 2012-01-27 PH PH1/2013/501528A patent/PH12013501528A1/en unknown
- 2012-01-27 EP EP12702947.8A patent/EP2670765B1/en active Active
- 2012-01-27 KR KR1020137023070A patent/KR101886467B1/ko not_active Expired - Fee Related
- 2012-01-27 AU AU2012212509A patent/AU2012212509B2/en not_active Ceased
- 2012-01-27 EA EA201391127A patent/EA022470B1/ru not_active IP Right Cessation
- 2012-01-27 JP JP2013551362A patent/JP6001560B2/ja not_active Expired - Fee Related
- 2012-01-27 SG SG2013056858A patent/SG192144A1/en unknown
- 2012-01-27 MY MYPI2013701325A patent/MY162186A/en unknown
- 2012-01-27 CN CN201280014966.XA patent/CN103429607B/zh active Active
- 2012-01-27 CA CA2826113A patent/CA2826113C/en active Active
- 2012-01-27 PT PT127029478T patent/PT2670765T/pt unknown
- 2012-01-27 PE PE2013001719A patent/PE20141152A1/es active IP Right Grant
- 2012-01-27 BR BR112013019419A patent/BR112013019419A2/pt not_active Application Discontinuation
- 2012-01-31 AR ARP120100314A patent/AR085053A1/es unknown
- 2012-01-31 TW TW101103140A patent/TWI628188B/zh not_active IP Right Cessation
- 2012-01-31 UY UY0001033886A patent/UY33886A/es not_active Application Discontinuation
-
2013
- 2013-07-26 TN TNP2013000321A patent/TN2013000321A1/fr unknown
- 2013-07-28 IL IL227678A patent/IL227678B/en active IP Right Grant
- 2013-07-30 CL CL2013002185A patent/CL2013002185A1/es unknown
- 2013-08-27 CO CO13203030A patent/CO6751275A2/es unknown
- 2013-08-30 ZA ZA2013/06546A patent/ZA201306546B/en unknown
-
2014
- 2014-07-24 US US14/339,572 patent/US20140343000A1/en not_active Abandoned
-
2016
- 2016-02-04 US US15/015,741 patent/US20160151387A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015510515A (ja) * | 2012-02-15 | 2015-04-09 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｉｖ成熟阻害活性のあるｃ−３シクロアルケニルトリテルペノイド |
| JP2015516422A (ja) * | 2012-05-07 | 2015-06-11 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｉｖ成熟阻害活性を有するｃ−１７二環式アミンのトリテルペノイド |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103429607B (zh) | 具有hiv成熟抑制活性的c-17和c-3经修饰的三萜系化合物 | |
| JP5755731B2 (ja) | Ｈｉｖ成熟阻害剤としての修飾ｃ−３ベツリン酸誘導体のｃ−２８アミド | |
| JP6000283B2 (ja) | Ｈｉｖ成熟阻害剤としてのｃ−３修飾ベツリン酸誘導体のｃ−２８アミン | |
| JP6155285B2 (ja) | Ｈｉｖ成熟阻害活性のあるｃ−３シクロアルケニルトリテルペノイド | |
| JP6212545B2 (ja) | Ｈｉｖ成熟阻害活性を有するｃ−１７二環式アミンのトリテルペノイド | |
| JP6186010B2 (ja) | Ｈｉｖ成熟阻害活性を有するｃ−１９修飾トリテルペノイド類 | |
| CA2944778C (en) | Triterpenoids with hiv maturation inhibitory activity | |
| ES2957767T3 (es) | Triterpenoides modificados en C-3 y C-17 como inhibidores del VIH-1 | |
| NZ614871B2 (en) | C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150106 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150106 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160105 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160325 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160823 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160901 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6001560 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |